Tango Therapeutics (NASDAQ:TNGX) Given New $8.00 Price Target at B. Riley

Tango Therapeutics (NASDAQ:TNGX) had its target price decreased by B. Riley from $16.00 to $8.00 in a report published on Monday,Benzinga reports. B. Riley currently has a buy rating on the stock.

Other analysts also recently issued research reports about the stock. Jefferies Financial Group started coverage on shares of Tango Therapeutics in a report on Wednesday, July 17th. They issued a “buy” rating and a $19.00 price objective for the company. Wedbush increased their price objective on shares of Tango Therapeutics from $11.00 to $13.00 and gave the company an “outperform” rating in a report on Thursday, August 8th. HC Wainwright reiterated a “buy” rating and issued a $13.00 price objective on shares of Tango Therapeutics in a report on Friday. Finally, Guggenheim cut their price objective on shares of Tango Therapeutics from $18.00 to $8.00 and set a “buy” rating for the company in a report on Thursday, November 7th. Eight equities research analysts have rated the stock with a buy rating, According to MarketBeat, Tango Therapeutics presently has a consensus rating of “Buy” and an average price target of $13.14.

Tango Therapeutics Stock Up 14.6 %

Shares of Tango Therapeutics stock opened at $3.38 on Monday. Tango Therapeutics has a twelve month low of $2.70 and a twelve month high of $13.01. The firm’s 50-day moving average price is $7.41 and its 200 day moving average price is $8.29.

Insider Transactions at Tango Therapeutics

In other news, insider Boxer Capital Management, Llc sold 625,000 shares of the firm’s stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $7.05, for a total transaction of $4,406,250.00. Following the completion of the sale, the insider now owns 7,573,642 shares in the company, valued at $53,394,176.10. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, insider Boxer Capital Management, Llc sold 625,000 shares of Tango Therapeutics stock in a transaction that occurred on Monday, October 21st. The shares were sold at an average price of $7.05, for a total value of $4,406,250.00. Following the completion of the sale, the insider now owns 7,573,642 shares in the company, valued at approximately $53,394,176.10. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Rock Ventures Iv L.P. Third sold 150,000 shares of Tango Therapeutics stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $10.09, for a total transaction of $1,513,500.00. Following the completion of the sale, the insider now owns 17,201,475 shares of the company’s stock, valued at $173,562,882.75. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 4,965,400 shares of company stock worth $25,156,782 in the last 90 days. Insiders own 6.30% of the company’s stock.

Institutional Trading of Tango Therapeutics

Several institutional investors have recently added to or reduced their stakes in the stock. Price T Rowe Associates Inc. MD increased its holdings in Tango Therapeutics by 12.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,771 shares of the company’s stock valued at $102,000 after purchasing an additional 1,426 shares during the last quarter. The Manufacturers Life Insurance Company boosted its position in Tango Therapeutics by 8.1% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 29,511 shares of the company’s stock valued at $253,000 after buying an additional 2,218 shares during the period. SG Americas Securities LLC boosted its position in Tango Therapeutics by 16.0% in the 1st quarter. SG Americas Securities LLC now owns 30,429 shares of the company’s stock valued at $242,000 after buying an additional 4,203 shares during the period. Point72 DIFC Ltd purchased a new position in Tango Therapeutics in the 2nd quarter valued at approximately $54,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its position in Tango Therapeutics by 32.6% in the 1st quarter. Mirae Asset Global Investments Co. Ltd. now owns 28,964 shares of the company’s stock valued at $230,000 after buying an additional 7,128 shares during the period. Institutional investors and hedge funds own 78.99% of the company’s stock.

Tango Therapeutics Company Profile

Tango Therapeutics, Inc, a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions.